Clinical Report: The Role of CAR T-Cell Therapies and Bispecific Antibodies

Overview

This editorial reviews CAR T-cell therapies and bispecific antibodies in treating hematologic malignancies, focusing on their efficacy and safety profiles.

Background

The treatment landscape for hematologic malignancies has evolved significantly over the past decade due to T-cell redirecting immunotherapy. CAR T-cell therapies and bispecific antibodies have improved outcomes for patients with relapsed or refractory B-cell lymphomas, leukemias, and multiple myeloma.

Data Highlights

No numerical data available in the source material.

Key Findings

• CAR-T therapy showed higher complete response rates (82%) compared to bispecific antibodies (65%) in relapsed/refractory follicular lymphoma.
• CD19/CD22 dual-targeted CAR-T therapy was found to be in a more advantageous efficacy-safety zone than CD3×CD20 bispecific antibodies.
• CAR-T therapy can be safely administered to patients with pre-existing Parkinson’s disease with appropriate monitoring and support.
• Sequential use of bispecific antibodies may serve as a bridging strategy while CAR-T cell manufacturing is underway.
• Management of toxicity is critical, with autologous stem cell boosts being effective for severe cytopenia from BCMA-directed bispecific antibody therapy.

Clinical Implications

Clinicians should consider the unique toxicity profiles and patient-specific factors when selecting between CAR-T therapies and bispecific antibodies.

Conclusion

The integration of CAR T-cell therapies and bispecific antibodies represents a significant advancement in the treatment of hematologic cancers, necessitating ongoing research and clinical vigilance to optimize patient outcomes.

Related Resources & Content

1. The ASCO Post, 2023 -- CAR T-Cell Therapies: Trends and Indications
2. Blood Cancer Journal, 2024 -- Comparative Analysis of Bispecific Antibodies and CAR-T Cell Therapies in Treating Large B-Cell Lymphomas
3. The ASCO Post, 2021 -- Surbhi Sidana, MD, Comments on CAR T-Cell Therapy and Bispecific Antibodies Targeting Myeloma
4. Frontiers in Immunology, 2026 -- Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology
5. PMC, 2026 -- 2026 Update on the Management of Diffuse Large B‐Cell Lymphoma
6. New England Journal of Medicine, 2023 -- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
7. Annals of Hematology, 2025 -- Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma
8. 2026 Update on the Management of Diffuse Large B‐Cell Lymphoma - PMC
9. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma | New England Journal of Medicine
10. Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies | Annals of Hematology | Springer Nature Link